APA (7th ed.) Citation

RF, O., BN, B., BE, G., JM, F., D, C., RA, B., . . . R, B. (2023). Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(25), 4077. https://doi.org/10.1200/JCO.22.02766

Chicago Style (17th ed.) Citation

RF, Ozols, et al. "Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 41, no. 25 (2023): 4077. https://doi.org/10.1200/JCO.22.02766.

MLA (9th ed.) Citation

RF, Ozols, et al. "Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 41, no. 25, 2023, p. 4077, https://doi.org/10.1200/JCO.22.02766.